EMBER-3 III期试验更新疗效:imlunestrant联合或不联合abemaciclib治疗晚期乳腺癌
EMBER-3研究在经内分泌治疗的ER阳性/HER2阴性晚期乳腺癌患者中比较imlunestrant、标准治疗(SOC)及imlunestrant-abemaciclib。更新分析显示,ESR1m患者中imlunestrant较SOC延长中位OS(34.5 vs 23.1个月,HR 0.60,P=0.0043,未达显著性界值);所有患者中联合组中位PFS 10.9 vs 5.5个月(HR 0.59,名义P<0.0001),OS无显著差异。
要点
- 所有患者中联合组中位PFS 10.9个月,优于imlunestrant单药5.5个月。
- imlunestrant为基础的全口服方案可作为经内分泌治疗患者的无化疗选择。
核心结论
- imlunestrant为基础方案对经内分泌治疗的ER阳性/HER2阴性晚期乳腺癌具临床获益,支持作为全口服无化疗选择。
研究设计与样本
- III期EMBER-3试验随机(1:1:1)纳入874例经芳香化酶抑制剂±CDK4/6抑制剂治疗的ER阳性/HER2阴性晚期乳腺癌患者。
- 分组:imlunestrant组331例,SOC(氟维司群或依西美坦)组330例,imlunestrant-abemaciclib组213例。
- 主要终点为ESR1m患者及所有患者中imlunestrant vs SOC的PFS,以及所有患者中imlunestrant-abemaciclib vs imlunestrant的PFS;OS为关键次要终点。
- 中位随访28.5个月,数据截止2025年8月18日,10.1%患者仍在治疗。
主要发现
- ESR1m患者中,imlunestrant组中位OS 34.5个月 vs SOC组23.1个月(HR 0.60,95%CI 0.43-0.86,P=0.0043,未达显著性界值)。
- 所有患者中,imlunestrant-abemaciclib组中位OS未达到 vs imlunestrant组34.4个月(HR 0.82,95%CI 0.59-1.16,P=0.2622)。
- 所有患者中,imlunestrant-abemaciclib组中位PFS 10.9个月 vs imlunestrant组5.5个月(HR 0.59,95%CI 0.47-0.74,名义P<0.0001)。
- 所有预设探索性终点均倾向于imlunestrant为基础方案,安全性与此前报告一致。
临床怎么用
- 对经芳香化酶抑制剂±CDK4/6抑制剂治疗的ER阳性/HER2阴性晚期乳腺癌,可考虑imlunestrant为基础的全口服无化疗方案。
局限性
- OS分析为预设中期分析,因仅两项PFS终点达到,传递至OS比较的显著性水平有限。
- imlunestrant-abemaciclib组样本量较小(n=213),OS数据未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At the primary progression-free survival (PFS) analysis, the phase III EMBER-3 trial in endocrine therapy-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant versus standard of care (SOC: fulvestrant or exemestane) in patients with ESR1 mutations (ESR1m) and with imlunestrant-abemaciclib versus imlunestrant in all patients, regardless of ESR1m. In this article, we report updated efficacy from a prespecified interim overall survival (OS) analysis. PATIENTS AND METHODS: Patients with ER-positive, HER2-negative ABC previously treated with aromatase inhibitors ± cyclin-dependent kinase 4 and 6 inhibitors were randomly assigned (1 : 1 : 1) to receive imlunestrant, SOC, and imlunestrant-abemaciclib. Primary endpoints were PFS in imlunestrant versus SOC in patients with ESR1m and all patients, and versus imlunestrant-abemaciclib in all concurrently randomized patients. OS was a key secondary endpoint (tested if the corresponding PFS was statistically significant). Due to only two of three PFS endpoints being met, a limited significance level was passed to the OS comparisons. Exploratory endpoints included time to chemotherapy, chemotherapy-free survival, and PFS2. RESULTS: A total of 874 patients were randomized (imlunestrant, n = 331; SOC, n = 330; imlunestrant-abemaciclib, n = 213). Median follow-up was 28.5 months; 10.1% of patients remained on treatment (data cut-off: 18 August 2025).In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached]. In all patients regardless of ESR1m, mOS was not reached with imlunestrant-abemaciclib versus 34.4 months with imlunestrant (HR 0.82, 95% CI 0.59-1.16, P = 0.2622). Updated PFS demonstrated sustained benefit. Notably, in all patients regardless of ESR1m, the median PFS of imlunestrant-abemaciclib versus imlunestrant was 10.9 versus 5.5 months (HR 0.59, 95% CI 0.47-0.74, nominal P < 0.0001). All prespecified exploratory endpoints favored imlunestrant-based regimens. Safety remains consistent with prior reports. CONCLUSIONS: These findings reinforce the clinical benefit of imlunestrant-based regimens as a potential all-oral, chemotherapy-free treatment option for endocrine-pretreated patients with ER-positive, HER2-negative ABC.
引用
- Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Ann Oncol. 2025. PMID: 41391667. doi:10.1016/j.annonc.2025.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。